BioXcel Therapeutics Inc
F:BX2
BioXcel Therapeutics Inc
F:BX2
Price:
2.56
EUR
Market Closed
Market Cap:
€96.1m
Relative Value
The Relative Value of one
BX2
stock under the Base Case scenario is
hidden
EUR.
Compared to the current market price of 2.56 EUR,
BioXcel Therapeutics Inc
is
hidden
.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
BX2 Relative Value
HIDDEN
Multiples Across Competitors
BX2 Competitors Multiples
BioXcel Therapeutics Inc Competitors
BioXcel Therapeutics Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
BioXcel Therapeutics Inc
F:BX2
|
30.2m EUR | 40.2 | -0.4 | -1.7 | -1.7 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
394.3B USD | 6.4 | 92.8 | 15.3 | 21.2 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
198.3B USD | 5.4 | 25.6 | 14.7 | 14.7 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
180.7B USD | 6.1 | 21.2 | 13.2 | 16.3 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
119.8B USD | 9.9 | 30.2 | 22.7 | 23.7 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78.8B USD | 5.5 | 17.5 | 12.9 | 14.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
68B AUD | 3.1 | 34.5 | 11.4 | 14.3 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 | |
| NL |
|
argenx SE
XBRU:ARGX
|
37.8B EUR | 10.6 | 34 | 36.8 | 37.6 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
